↓ Skip to main content

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Overview of attention for article published in The Lancet Haematology, November 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#21 of 1,307)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
39 news outlets
blogs
2 blogs
twitter
31 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
54 Dimensions

Readers on

mendeley
39 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
Published in
The Lancet Haematology, November 2022
DOI 10.1016/s2352-3026(22)00292-7
Pubmed ID
Authors

Justin M Watts, Maria R Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J Schiller, Shira N Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S Wang, Karen P Seiter, Andrew H Wei, Stephane De Botton, Montserrat Arnan, Will Donnellan, Anthony P Schwarer, Christian Récher, Brian A Jonas, P Brent Ferrell, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jorge E Cortes

X Demographics

X Demographics

The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 39 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 39 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 13%
Student > Bachelor 5 13%
Student > Ph. D. Student 3 8%
Other 2 5%
Lecturer > Senior Lecturer 2 5%
Other 3 8%
Unknown 19 49%
Readers by discipline Count As %
Medicine and Dentistry 7 18%
Biochemistry, Genetics and Molecular Biology 5 13%
Agricultural and Biological Sciences 3 8%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Materials Science 1 3%
Other 0 0%
Unknown 22 56%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 321. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2023.
All research outputs
#108,241
of 25,982,087 outputs
Outputs from The Lancet Haematology
#21
of 1,307 outputs
Outputs of similar age
#3,053
of 443,567 outputs
Outputs of similar age from The Lancet Haematology
#1
of 46 outputs
Altmetric has tracked 25,982,087 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,307 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 29.6. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 443,567 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.